American Journal of Kidney Diseases
Volume 51, Issue 3 , Pages 370-372 , March 2008

Efficacy and Safety of Combined Use of Aliskiren and Valsartan in Patients With Hypertension

  • Nathaniel Berman, MD

      Affiliations

    • Corresponding Author InformationAddress correspondence to Nathaniel Berman, Albert Einstein College of Medicine, Jack and Pearl Resnick Campus, 1300 Morris Park Avenue, Ullmann Building, Room 615, Bronx, NY 10461.
    • ,
  • Thomas Hostetter, MD

References 

  1. Oparil S, Yarows SA, Patel S, Fang H, Zhang J, Satlin A. Efficacy and safety of combined use of aliskiren and valsartan in patients with hypertension: A randomised, double-blind trial. Lancet. 2007;370:221–229
  2. Pool JL, Schmieder RE, Azizi M, et al. Aliskiren, an orally effective renin inhibitor, provides anti-hypertensive efficacy alone and in combination with valsartan. Am J Hypertens. 2007;20:11–20
  3. Azizi M, Menard J, Bissery A, et al. Pharmacologic demonstration of the synergistic effects of a combination of the renin inhibitor aliskiren and the AT1 receptor blocker valsartan on the angiotensin II-renin feedback interruption. J Am Soc Nephrol. 2004;15:3126–3133
  4. Azizi M, Menard J, Bissery A, Guyenne TT, Bura-Riviere A. Hormonal and hemodynamic effects of aliskiren and valsartan and their combination in sodium-replete normotensive individuals. Clin J Am Soc Nephrol. 2007;2:947–955
  5. Jennings DL, Klaus JS, Comleman CI, Manierski C, Yee J. Combination therapy with an ACE inhibitor and an angiotensin receptor blocker for diabetic nephropathy: A meta-analysis. Diabet Med. 2007;24:486–493
  6. Kunz R, Friedrich C, Wolbers M, Mann JF. Meta-analysis: Effect of monotherapy and combination therapy with inhibitors of the renin-angiotensin system on proteinuria in renal disease. Ann Intern Med. 2008;148:30–48
  7. Nakao N, Yoshimura A, Morita H, Takada M, Kayano T, Ideura T. Combination treatment of angiotensin-II receptor blocker and angiotensin-converting-enzyme inhibitor in non-diabetic renal disease (COOPERATE): A randomized controlled trial. Lancet. 2003;361:117–124
  8. Bakris GL, Ruilope L, Locatelli F, et al. Treatment of microalbuminuria in hypertensive subjects with elevated cardiovascular risk: Results of the IMPROVE trial. Kidney Int. 2007;72:879–885
  9. Epstein M, Williams GH, Weinberger M, et al. Selective aldosterone blockade with eplerenone reduces albuminuria in patients with type 2 diabetes. Clin J Am Soc Nephrol. 2006;1:940–951
  10. Huang Y, Noble NA, Zhang J, Xu C, Border WA. Renin-stimulated TGF-beta1 expression is regulated by a mitogen-activated kinase in mesangial cells. Kidney Int. 2007;72:45–52
  11. Fried LF, Duckworth WC. Combination angiotensin receptor blocker and angiotensin converting enzyme inhibitor for treatment of diabetic nephropathy VA NEPHRON-D Study. NIH clinical trials website http://clinicaltrials.gov/ct2/show/NCT00555217?term=NCT00555217&rank=1Accessed December 5, 2007

 Originally published online as doi:10.1053/j.ajkd.2007.12.009 on February 6, 2008.

PII: S0272-6386(07)01605-8

doi: 10.1053/j.ajkd.2007.12.009

American Journal of Kidney Diseases
Volume 51, Issue 3 , Pages 370-372 , March 2008

Article Tools